Autolus Therapeutics
AUTL | NASDAQ
$1.16
-$0.01 (-0.85%)
At close: Nov 16, 2026, 3:59 PM ET
$1.14
-$0.02 (-1.72%)
After-hours:
Nov 16, 2026, 7:39 PM ET
-0.85%
(1D)No price chart data available for 1D timeframe.
Rating
40
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #528/1021 (Top 52%)
Key Statistics
Market Data
Market Cap $307.42M
1D Range
1.07 1.17
52W Range
1.07 2.54
Valuation (TTM)
PE -1.20
PB 11.22
EV/EBITDA -1.05
Valuation (NTM)
Forward PE N/A
Forward PEG 0.06
Price Target $8.00
Cash Flow
FCF Yield -66.6%
SBC Adj. FCF Yield -71.3%
SBC Impact -7.0%
Margins
Gross Margin 35.8%
Operating Margin -159.6%
FCF Margin -149.1%
Growth (CAGR)
Revenue 3Y | 5Y 191.9% |
121.9%
Dil EPS 3Y | 5Y 11.9% |
17.1%
FCF 3Y | 5Y 0.2% |
-16.0%
Returns
ROA -48.9%
ROE -263.1%
ROIC -51.1%
Financial Health
Net Cash
$181.56M
Current Ratio 3.72
Interest Coverage -4.29
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes s...
Sector Healthcare
Industry Biotechnology
Employees 752
IPO Date Jun 22, 2018
Website www.autolus.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 10, 2026
EPS
-$0.21
Beat 0.00%
YoY:
+30.00% REV
$41.24M
Beat +4.30%
YoY:
+94.57%Next Earnings
Mar 10, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$8.00
Upside
+589.66%
Buy (3)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove AUTL